Eplontersen,Inotersen
Ionis Pharmaceuticals,Akcea Therapeutics,Astrazeneca
[]
neuro-ttransform phase iii results presented at aan showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks #aan #consistent #demonstrated #disease #eplontersen #iii 
Today's News for Tomorrow's Investor
📈 Do your own DD
🇨🇦  #TSX #TSXV #CSEstocks
🇺🇸  #OTCmarkets